Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study

Chenbin Liu¹ | Terence T. Sio¹ | Wei Deng¹ | Jie Shan² | Thomas B. Daniels¹ | William G. Rule¹ | Pedro R. Lara¹ | Shawn M. Korte¹ | Jiajian Shen¹ | Xiaoning Ding¹ | Steven E. Schild¹ | Martin Bues¹ | Wei Liu¹

¹Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA
²Department of Biomedical Informatics, Arizona State University, Tempe, AZ, USA

Author to whom correspondence should be addressed. Wei Liu
E-mail: liu.wei@mayo.edu.

Funding Information
National Cancer Institute (NCI)

Abstract

Purpose: To compare dosimetric performance of volumetric-modulated arc therapy (VMAT) and small-spot intensity-modulated proton therapy for stage III non-small-cell lung cancer (NSCLC).

Methods and Materials: A total of 24 NSCLC patients were retrospectively reviewed; 12 patients received intensity-modulated proton therapy (IMPT) and the remaining 12 received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTV) on averaged 4D-CTs. The dose-volume-histograms (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases of each field per fraction. DVH indices were compared using Wilcoxon rank sum test.

Results: Compared with VMAT, IMPT delivered significantly lower cord Dmax, heart Dmean, and lung V5 Gy[RBE] with comparable CTV dose homogeneity, and protection of other OARs. In terms of plan robustness, the IMPT plans were statistically better than VMAT plans in heart Dmean, but were statistically worse in CTV dose coverage, cord Dmax, lung Dmean, and V5 Gy[RBE]. Other DVH indices were comparable. The IMPT plans still met the standard clinical requirements with interplay effects considered.

Conclusions: Small-spot IMPT improves cord, heart, and lung sparing compared to VMAT and achieves clinically acceptable plan robustness at least for the patients included in this study with motion amplitude less than 11 mm. Our study supports the usage of IMPT to treat some lung cancer patients.

PACS
87.50.cm

KEY WORDS
intensity-modulated proton therapy, interplay effects, lung cancer, volumetric-modulated arc therapy
1 | INTRODUCTION

Lung cancer is the leading cause of cancer death among both men and women in the United States. Non-small-cell lung cancers (NSCLC) account for about 85% of lung cancer cases.\(^1\)\(^2\) Radiotherapy combined with chemotherapy is standard treatment for stage III NSCLC patients with unresectable tumors, but the potential toxic effects of radiation limit the feasibility for delivering adequate tumoricidal dose to targets in most patients.\(^3\)\(^4\) With photon radiation and concurrent chemotherapy, the long-term results from RTOG 0617 reported 5-year overall survival (5-year OS) of 32.1% (standard dose arm with 60 Gy) and 23% (high dose arm of 74 Gy) for unresectable NSCLC patients.\(^5\) The fact that dose escalation has led to worse overall survival is possibly due to higher cardiac toxicity.\(^6\)\(^7\) The improvement of overall survival would require the minimization of incidental radiation dose to critical normal structures.

Volumetric-modulated arc therapy (VMAT) is an advanced form of intensity-modulated radiation therapy (IMRT) that can deliver a precisely sculpted dose distribution using a single or multi-arcs.\(^7\) It has gained popularity in treating lung cancer patients due to its superior dose coverage, decreased radiation-induced pneumonitis, and shorter delivery time compared to conventional static-field IMRT.\(^8\)\(^9\)\(^10\)\(^11\) On the other hand, due to the sharp falloff of dose deposition distal to the Bragg peak, proton therapy has great potential to provide highly conformal tumor target coverage while sparing adjacent organs at risk (OARs), such as heart, lungs, spinal cord, and esophagus.\(^12\)\(^13\) Proton therapy is used in three different modalities: passive-scattering proton therapy (PSPT), uniform scanning proton therapy (USPT), and intensity-modulated proton therapy (IMPT). Recently, Chang et al.\(^14\) published a phase 2 study of high dose spot IMPT (74 Gy[RBE]) and concurrent chemotherapy for unresectable stage III NSCLC. They reported 5-year OS of 29% with very low rates of toxicities. It seemed that high dose PSPT tended to have better 5-year OS than the high dose proton therapy, but still slightly worse outcomes than the standard dose photon therapy if we compared this clinical trial data to RTOG 0617. Therefore, they suggested the use of IMPT to further improve the dose conformity and reduce doses to nearby OARs.\(^15\)\(^16\)

Unfortunately, IMPT is subject to increased uncertainties for moving targets compared with PSPT and USPT.\(^17\)\(^18\)\(^19\) Previous studies used proton pencil beam machines with in-air sigma at the isocenter as large as 6–15 mm (depending on proton energy) to treat NSCLC cancer.\(^15\)\(^16\) In this study, we defined these machines as large-spot proton machines compared to the proton pencil beam machines with in-air sigma at the isocenter of 2–6 mm (depending on proton energy), which we defined as small-spot proton machines for the purpose of this study. There is a concern that IMPT with small-spot size may not be a good option for lung cancer treatments with large motions, due to the concerns of uncertainties and interplay effects.\(^20\) A study by Chang et al. suggested that thoracic malignancies with tumor motion larger than 5 mm may not be safely treated using IMPT.\(^21\) Other studies suggested that IMPT treatment may be used for tumors with motion larger than 5 mm, but it would be negatively impacted by interplay effects, especially for small-spot IMPT.\(^22\)\(^23\)\(^24\)\(^25\) There are some studies that reported the limited impact of uncertainties and interplay effects in robustly optimized IMPT for stage III NSCLC.\(^26\)\(^27\) There are no reports about dosimetric comparison between small-spot IMPT and VMAT for NSCLC patients in term of plan quality, plan robustness in the face of uncertainties, and interplay effects.

IMPT with small-spot sizes has been used to treat non-moving targets for years. However, for moving targets such as lung cancer, previous researchers did demonstrate that small-spot IMPT could improve the treatment plan quality.\(^28\)\(^29\) However, a simulation study showed that small-spot IMPT (σ: 2–4 mm) could be less robust toward motion and interplay effects than large-spot IMPT (σ: 8–17 mm).\(^30\) Larger number of spots will be needed to cover the same target volume if small-spot proton machine was applied, which was also reported in a recent study.\(^31\) In the same study it was stated that interplay effects should be considered before IMPT treatment plan was delivered to lung cancer patients.\(^32\)

Majority of the new proton centers being developed are equipped with spot scanning beam with small-spot size (in-air sigma at the isocenter as large as 2–6 mm) only. Currently, there are no studies sharing clinical experience in radiation oncology community concerning the treatment of stage III NSCLC patients with small-spot IMPT. In this study, we reported the procedure implemented at our institution for small-spot IMPT in the treatment of NSCLC patients. The study focused on the evaluation of plan quality, robustness and interplay effects, and compared the dosimetric parameters of small-spot IMPT and VMAT.

2 | MATERIALS AND METHODS

2.A | Patient selection

We retrospectively reviewed 12 unresectable stage III NSCLC patients treated with IMPT consecutively between March 2016 and June 2017 at our institution. In addition, we retrospectively reviewed 12 selected stage III NSCLC patients treated by VMAT in the same time period at our institution. All plans used in this work were the clinically applied.

The patients included in this study were carefully selected by experienced physicists from the existing database of treated patients to ensure that the patients from the two treatment groups did not show significant differences in age, motion amplitude, or prescription doses (Table 1). However, the tumor size of patients treated by IMPT was significantly larger than that of patients treated with VMAT. All patients were staged using PET/CT and brain CT scans to rule out metastatic disease. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and were definitively treated with radiation therapy with curative intent. None of the patients had implanted cardiac devices.

2.B | Patient simulation and immobilization

All patients were simulated using four-dimensional computed tomography (4D CT) in the supine position. Before image acquisition, the
patient thorax was immobilized using Orfit board (Orfit Industries, Wijnenegem, Belgium) and thermoplastic masks. The respiratory motion amplitude was defined by measuring the largest tumor mass center displacement in the three canonical directions in all 10 phases of the 4D CT. All patients selected for this study had motion amplitudes smaller than 11 mm. The 4D CT data sets were transferred to a commercial treatment planning system (Eclipse™, Varian medical system, Palo Alto, CA, USA) for localization of targets and contouring of OARs.

2.C | Target and normal tissue definition

Treatment targets were defined as follows. Co-registration with contrast enhanced CT scans and/or PET scans were used in identifying the gross target volume (GTV). The internal gross target volume (iGTV) was designed to encompass the extent of GTV motion in all phases of 4D CT. The clinical target volume (CTV) was formed by isotropic expansion of the iGTV by 5–10 mm (typically 7–8 mm). The value of margin expansions were based on the pathology of tumors and determined by experienced radiation oncologists. The CTV was adjusted based on patterns of potential tumor extent and anatomic boundaries such as vertebral body, chest wall, and heart, etc. Planning target volumes (PTVs) formed by 5 mm uniform expansion of CTVs were used for plan optimization and evaluation in VMAT. All normal tissues were contoured on the 4D averaged CT. CT artifacts were overridden using HU values sampled nearby.

2.D | Treatment planning

IMPT treatment planning generally followed the treatment planning guidelines recommended by the Particle Therapy Co-Operative Group (PTCOG) Thoracic and Lymphoma Subcommittee. The proton beam scanning machine for IMPT treatment was commissioned to have an energy-dependent spot size (in-air σ) of 2 mm to 6 mm and a fixed spot spacing of 5 mm was chosen in treatment planning. Discrete proton energies (from 71.3 to 228.8 MeV) were selected to minimize the ripple in the spread out Bragg peak (SOBP) dose distributions along the beam direction. VMAT treatment was administered using CLINAC machines (Varian Medical System, Palo Alto, CA, USA).

All IMPT plans were generated on the averaged 4D CT with iGTV density override (HU = 50). During the initial spot arrangement, an additional 7 mm margin expansion based on the PTV was used in the IMPT planning to ensure that there was at least one spot outside of the PTV to generate a possible homogeneous dose distribution within the PTV.

In most cases, two or three beams were used in IMPT. Beam directions in IMPT were chosen by dosimetrists with the help of experienced physicists if needed to minimize the impact of motion and spare normal tissues. Ten of twelve IMPT plans required single field optimization (SFO). If the SFO plan could not meet dosimetric and robustness requirements, a multiple field optimization (MFO) plan using robust optimization was generated. The final plan was chosen by an experienced radiation oncologist after careful evaluation of plan quality, plan robustness, and interplay effects.

For IMPT plans, two verification plans were generated by recalculating the dose on the exhale and inhale 4D CT phases (without the density override) to evaluate the impact of respiratory motion. The original plan was adjusted until the verification and original plan dose distributions met all the required dose volume constraints (Table 2), plan robustness quantification thresholds, and the prescription criteria (see 2.F subsection).

In VMAT treatment planning, PTV was used for plan optimization. We applied photon optimizer (PO) model in the Eclipse™ for VMAT optimization, and analytical anisotropic algorithm (AAA) model for dose calculation. For target coverage, PTVhigh V100% was at least 95% of prescription dose, and PTVhigh D0.03 cc was not more than 110% of prescription dose. Most commonly, two or three arcs were used.

2.E | Plan quality evaluation

We calculated CTV D25%, D5% (the dose level covering at least 25% and 5% of the structure volume with the highest dose respectively).

| Structure              | Dose limits (Gy[RBE])                                      |
|------------------------|------------------------------------------------------------|
| Esophagus              | D25% < 65; D5% < 55; Dwhole volume ≤ 45, as low as reasonably achievable |
| Liver                  | Dwhole volume ≤ 25; D50% ≤ 35                              |
| Total normal lung      | V20 Gy[RBE] < 37% is desirable; V20 Gy[RBE] > 41% is a major deviation |
| Spinal cord            | Dmax ≤ 50                                                  |
| Heart                  | D25% < 60; D5% < 45; Dwhole volume ≤ 30, as low as reasonably achievable; V50 < 25%; Dmean < 20 |
| Skin                   | Dmax ≤ 55 (decided by the treating physician)               |

| TABLE 2 | Dose volume constraints for organs at risk. |

| Structure              | Dose limits (Gy[RBE])                                      |
|------------------------|------------------------------------------------------------|
| Esophagus              | D25% < 65; D5% < 55; Dwhole volume ≤ 45, as low as reasonably achievable |
| Liver                  | Dwhole volume ≤ 25; D50% ≤ 35                              |
| Total normal lung      | V20 Gy[RBE] < 37% is desirable; V20 Gy[RBE] > 41% is a major deviation |
| Spinal cord            | Dmax ≤ 50                                                  |
| Heart                  | D25% < 60; D5% < 45; Dwhole volume ≤ 30, as low as reasonably achievable; V50 < 25%; Dmean < 20 |
| Skin                   | Dmax ≤ 55 (decided by the treating physician)               |
and $D_{2cc}$ (the minimum dose for the 2 cc of the structure receiving the highest dose) from the CTV dose-volume-histograms (DVH). CTV $D_{5\%}$, $D_{5\%}$-$D_{95\%}$, and $D_{2cc}$ were used to indicate CTV dose coverage, dose homogeneity, and hot spots, respectively. The CTV was chosen as the target consistent with our clinical practice. The OAR doses evaluated were spinal cord $D_{max}$, esophagus $D_{mean}$, lung $D_{mean}$, and heart $D_{mean}$. In addition, relative volumes such as, total normal lung $V_5\text{Gy}[\text{RBE}]$ and $V_{20}\text{Gy}[\text{RBE}]$, esophagus $V_{60}\text{Gy}[\text{RBE}]$, and heart $V_{50}\text{Gy}[\text{RBE}]$ were calculated. $V_{X\text{Gy}[\text{RBE}]}$ was defined as the normalized volume receiving a dose of at least $X$ Gy[\text{RBE}].

### 2.F | Robustness quantification

To evaluate the robustness of IMPT and VMAT plans, we used the DVH band width as a numerical index: the smaller width value means better plan robustness.

For IMPT plans, we considered 12 perturbed scenarios and one nominal scenario. The range uncertainty due to the CT calibration error was assumed to be $\pm 3.5\%$ of the nominal beam ranges, and the isocenter of the patient was rigidly shifted in the antero-posterior (A-P), superior-inferior (S-I), and right-left (R-L) directions by 5 mm, respectively. Combining range and isocenter shift yielded 12 perturbed scenarios.

For VMAT plans, we created six perturbed scenarios and one nominal scenario. The setup uncertainty caused by the rigid shift of the patient isocenter in the A-P, S-I, and R-L directions ($\pm 5$mm) produced six perturbed scenarios. To generate these uncertainty scenarios, we manually shifted the isocenter ($\pm 5$mm) and recalculated the VMAT plans in different uncertainty scenarios. DVH curves for these scenarios were determined in our TPS. We exported the DVH curves and calculated the width of DVH band using in-house developed software. We ensured that in the worst-case scenario the CTV $D_{5\%}$ was at least 95% of the prescription dose in the dose calculations done on all CTs.

### 2.G | Interplay effect evaluation

For IMPT treatment, the average energy layer switch time for all 97 energies was 1.91s, ranging from 1.9 to 2.0 s. The average spill time was 1.93 ms. The effective magnet scanning speed in $x$-direction for high/medium and low energy groups were 5.7 and 7.0 m/s, respectively. The effective magnet scanning speed in $y$-direction for high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively. The proton spill rate in high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively. The effective magnet scanning speed in $x$-direction for high, medium, and low energy groups were 5.7 and 7.0 m/s, respectively. The proton spill rate in high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively. The effective magnet scanning speed in $y$-direction for high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively. The proton spill rate in high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively. The effective magnet scanning speed in $x$-direction for high, medium, and low energy groups were 5.7 and 7.0 m/s, respectively. The proton spill rate in high, medium, and low energy groups were 17.1, 18.2, and 22.2 m/s, respectively.

Iso-layer repainting was used to mitigate the impact of interplay effects. If the respiratory motion amplitude was less than 5 mm, the minimum and maximum MU limits in the proton machine were 0.003 and 0.04 MU, respectively. Otherwise, they were 0.003 and 0.01 MU, respectively. Smaller maximum MU limits thereby enforced a higher number of iso-layer repainting for these patients to mitigate interplay effects. For our iso-layer repainting technique, a spot would be split into multiple spots if its intensity was larger than the maximum MU limit and the split spots would be appended at the end of the spot list of the same energy layer and delivered through the iso-layer repainting. A spot, which is planned to deliver MUs smaller than the minimum MU limit, would be rounded up or down depending on whether the amount of MU was larger or smaller than half of the minimum MU limit. For example, with a minimum/maximum MU limit of 0.003/0.04 MU, a spot of 0.081 MU would be split into two spots of 0.04 MU, and the remaining 0.001 MU would be discarded since it was less than half of the minimum MU limit (0.0015 MU); a spot of 0.042 MU would be split into one spot of 0.04 MU and one spot of 0.003 MU, since the remaining 0.002 MU was larger than 0.0015 MU.

For IMPT plans, we developed software to calculate the dose under the influence of interplay effects. In the software, time-dependent spot delivery parameters, 4D CTs, and the time spent in each phase during the 4D CT simulations were used to calculate the dose delivered in a patient with interplay effects considered. We randomized the starting phase of each field per fraction to effectively mitigate the impact of the starting phase.

### 2.H | Statistical analysis

In order to allow for a fair comparison, all IMPT and VMAT plans were normalized to have a CTV $D_{5\%}$ of 100% of the prescription dose in the nominal scenario. We used the Wilcoxon rank sum test included in MATLAB® 2013 to compare all evaluation metrics. P-values less than 0.05 were considered statistically significant. The points located outside 1.5 times the interquartile range above the upper quartile and below the lower quartile were considered as maximum and minimum outliers, respectively.

| Table 3 The comparison of plan quality using DVH indices. |
|-----------------|---------------|---------------|---------------|
| DVH index       | VMAT          | IMPT          | P-value       |
| CTV $D_{2cc}$ (normalized) | 105%          | 106%          | 0.47          |
| CTV $D_{5\%}$-$D_{95\%}$ (normalized) | 4.4%          | 4.1%          | 0.29          |
| Total lung $V_5\text{Gy}[\text{RBE}]$ (%) | 59.98%        | 29.39%        | 0.0014        |
| Total lung $V_{20}\text{Gy}[\text{RBE}]$ (%) | 24.37%        | 20.41%        | 0.51          |
| Total lung $D_{mean}$ (Gy[\text{RBE}]) | 13.56         | 10.65         | 0.24          |
| Esophagus $V_{60}\text{Gy}[\text{RBE}]$ (%) | 1.18%         | 9.63%         | 0.47          |
| Esophagus $D_{mean}$ (Gy[\text{RBE}]) | 17.02         | 20.58         | 0.14          |
| Heart $V_{50}\text{Gy}[\text{RBE}]$ (%) | 0.83%         | 0.83%         | 0.64          |
| Heart $D_{mean}$ (Gy[\text{RBE}]) | 6.97          | 1.60          | 0.017         |
| Spinal cord $D_{max}$ (Gy[\text{RBE}]) | 38.99         | 26.50         | 0.0011        |

Bold values represent significant difference between IMPT and VMAT DVH indices.
3 | RESULTS

3.A | Plan quality

We compared the plan quality in the nominal scenario (without any uncertainties considered). The IMPT plans performed significantly better in terms of spinal cord $D_{\text{max}}$, heart $D_{\text{mean}}$, and total lung $V_{5\text{ Gy}[RBE]}$ [Figs. 1(a)–1(d), Table 3]. Compared to the VMAT plans, IMPT plans had comparable $D_{2\text{ cc}}$ (normalized by the prescription doses), comparable CTV $D_{5\%}$-$D_{95\%}$ (normalized by the prescription doses), and comparable protection of most of the other OARs (esophagus $D_{\text{mean}}$, total lung $D_{\text{mean}}$, total lung $V_{5\text{ Gy}[RBE]}$, esophagus $V_{60\text{ Gy}[RBE]}$, and heart $V_{50\text{ Gy}[RBE]}$) [Figs. 1(a)–1(d), Table 3].

3.B | Plan robustness

Figures 2(a)–2(d) displayed the ranges of DVH band widths of CTV and OARs for all 24 patients to indicate plan robustness. $P$-values are displayed on the top of the columns. The robustness of IMPT plans was statistically better than that of VMAT plans for heart $D_{\text{mean}}$, but was statistically worse than that of VMAT plans for CTV $D_{95\%}$ (normalized by the prescription doses), spinal cord $D_{\text{max}}$, and total lung $D_{\text{mean}}$ and $V_{5\text{ Gy}[RBE]}$. The robustness of IMPT plans was comparable to that of VMAT plans for $D_{2\text{ cc}}$ (normalized by the prescription doses), CTV $D_{5\%}$-$D_{95\%}$ (normalized by the prescription doses), esophagus $D_{\text{mean}}$, $V_{60\text{ Gy}[RBE]}$, total lung $V_{20\text{ Gy}[RBE]}$ and heart $V_{50\text{ Gy}[RBE]}$ (Table 4).

3.C | Interplay effect

Interplay effects were only considered for the IMPT plans as shown in Figs. 3(a)–3(d). The median values of CTV $D_{95\%}$, $D_{2\text{ cc}}$, and $D_{5\%}$-$D_{95\%}$ (normalized by the prescription doses) are 0.98, 1.06, and 0.062, respectively. Median values of esophagus $D_{\text{mean}}$, total lung $D_{\text{mean}}$, spinal cord $D_{\text{max}}$, and heart $D_{\text{mean}}$ are 19.68 Gy[RBE], 9.38 Gy[RBE], 29.39 Gy[RBE], and 0.94 Gy[RBE], respectively. Median values of esophagus $V_{60\text{ Gy}[RBE]}$, total lung $V_{5\text{ Gy}[RBE]}$ and $V_{20\text{ Gy}[RBE]}$, heart $V_{50\text{ Gy}[RBE]}$ are 13.18%, 28.93%, 17.51%, and 0.02%, respectively.

4 | DISCUSSION

The present study was a treatment planning study, comparing results of small-spot IMPT treatment planning with results of VMAT treatment planning for patients with stage III NSCLC. Compared to VMAT, IMPT achieved a better protection of spinal cord, heart, and esophagus, and total normal lungs with comparable target homogeneity and hot spot. As for plan robustness, IMPT plans performed better than VMAT in heart $D_{\text{mean}}$, and comparable for CTV $D_{2\text{ cc}}$.
CTV D95% and D2cc. (b) Normalized CTV D2cc–D95%. (c) Esophagus Dmean, lung Dmean, cord Dmax, and heart Dmean. (d) Lung V5 Gy[RBE] and V20 Gy[RBE], esophagus V50 Gy[RBE], and heart V50 Gy[RBE]. Numbers at the top of the columns are P-values from Wilcoxon rank sum test. Abbreviations: RBE, relative biological effectiveness.

**Figure 2.** Comparison of plan robustness using the averaged widths from the DVH band method between IMPT and VMAT plans. (a) Normalized CTV D95% and D2cc. (b) Normalized CTV D2cc–D95%. (c) Esophagus Dmean, lung Dmean, cord Dmax, and heart Dmean. (d) Lung V5 Gy[RBE] and V20 Gy[RBE], esophagus V50 Gy[RBE], and heart V50 Gy[RBE]. Numbers at the top of the columns are P-values from Wilcoxon rank sum test. Abbreviations: RBE, relative biological effectiveness.

| DVH index | VMAT | IMPT | P-value |
|-----------|------|------|---------|
| CTV D95% (normalized) | 1.2% | 2.5% | 0.0061 |
| CTV D2cc (normalized) | 1.8% | 2.0% | 0.75 |
| CTV D2cc–D95% (normalized) | 2.3% | 3.1% | 0.13 |
| Total lung V5 Gy[RBE] (%) | 3.89% | 6.56% | 0.026 |
| Total lung V20 Gy[RBE] (%) | 2.23% | 3.41% | 0.053 |
| Total lung Dmean (Gy[RBE]) | 0.79 | 1.70 | 0.0007 |
| Esophagus V50 Gy[RBE] (%) | 4.96% | 3.81% | 0.84 |
| Esophagus Dmean (Gy[RBE]) | 3.93 | 4.00 | 0.67 |
| Heart V50 Gy[RBE] (%) | 1.30% | 0.85% | 0.54 |
| Heart Dmean (Gy[RBE]) | 2.62 | 1.48 | 0.0035 |
| Spinal cord Dmax (Gy[RBE]) | 4.43 | 3.43 | 0.035 |

Bold values represent significant difference between IMPT and VMAT DVH indices.

CTV D2cc–D95%, esophagus Dmean, and V20 Gy[RBE], lung V20 Gy[RBE], and heart V50 Gy[RBE], but worse for CTV D95%, spinal cord Dmax, lung Dmean, and V5 Gy[RBE].

VMAT gained popularity in the treatment of lung cancer patients due to its high conformity between the prescription iso-dose lines and targets. IMPT can spare more normal tissues than IMRT, including heart, spinal cord, lung, and esophagus, due to the characteristics of the Bragg peak. Compared with IMRT, IMPT significantly reduced mean lung dose by 2.8 Gy[RBE] and significantly reduced the lung volumes receiving 5 Gy, 10 Gy, and 20 Gy (p < 0.0001). In our study, IMPT achieved as good plan quality as VMAT in terms of target dose coverage, homogeneity, and sparing of the most OARs. More importantly IMPT significantly lowered heart mean dose, spinal cord maximum dose, and lung V20 Gy[RBE] compared to VMAT. Thus, IMPT may reduce the risks of radiation-induced cardiac toxicities, neurologic damage, and pneumonitis, and potentially improve the long-term quality of life of the NSCLC patients.

However, the effectiveness of a treatment plan also depends on plan robustness to both uncertainties and interplay effects. Compared with IMPT, VMAT is more robust with respect to motions or changes in anatomy, which is consistent with our study. IMPT could be enormously impacted by interplay effects for tumor motions larger than 10 mm and utilization of small-spot. Interestingly, our results show that IMPT can achieve clinically acceptable plan robustness in the presence of uncertainties. Additionally, with interplay effects considered, the IMPT plans mostly met the clinical requirements except for patient 10. Patient 10 had large amplitude of respiratory motion (11 mm) and a small target (CTV: 47.36 cm³). Both would lead to more severe interplay effects. Due to the proper planning method we used, uncertainties and respiratory motion had limited impact on target coverage and homogeneity, and
OAR protection, which is consistent with Inoue et al. Our results are consistent with Inoue et al. This is possibly due to the proper planning methods we used. Most of the IMPT plans included in this study were generated using SFO and the rest of them were generated using MFO with robust optimization from a commercial treatment planning system. Li et al. cautiously extended their IMPT treatment with large spots to lung cancer patients with tumor motion over 5 mm. Our study further extended the applicability of small-spot IMPT to treat lung cancer patients with tumor motions larger than 5 mm but smaller than 11 mm.

The patient groups selected for comparison are not completely statistically comparable. CTV volumes of the patients treated by IMPT are larger than those of the patients treated by VMAT (Table 1). A previous study suggested that large volumes could benefit plan robustness, but increase the difficulties in generating a plan of high quality in the case of IMPT. In our research, for patients with larger tumor volumes, IMPT still provided better plan quality than VMAT for patients with smaller tumor volumes, and generated treatment plans with clinically acceptable plan robustness. This further supports that new proton centers equipped with proton beam scanning machines with small-spot may treat locally advanced NSCLC, since IMPT plans are superior to VMAT plans even in a patient group with bigger tumor volumes.

This study has certain limitations. The number of the patients included in this study was small and not matched. A study with a larger patient population with both VMAT and IMPT plans is warranted to generalize our conclusions. Impact from target size and number of repainting remains important topics for future work.

5 | CONCLUSION

Small-spot IMPT significantly improves sparing of spinal cord, heart, and lung compared to VMAT and achieves clinically acceptable plan robustness at least for the lung cancer patients included in this study with motion amplitude less than 11 mm. The impact of interplay effects is small if procedures described here are used. This study supports the feasibility of clinical use of small-spot IMPT to treat certain lung cancer patients.

ACKNOWLEDGMENTS

This research was supported by the National Cancer Institute (NCI) Career Developmental Award K25CA168984, by Arizona Biomedical Research Commission Investigator Award, by the Fraternal Order of Eagles Cancer Research Fund Career Development Award, by The Lawrence W. and Marilyn W. Mattox Foundation for Cancer Research, by Mayo Arizona State University Seed Grant, and by The Kemper Marley Foundation.
CONFLICTS OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. New Eng J Med. 2008;359:1367–1380.
3. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289.
4. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2016;35:56–62.
5. Bradley J, Hu C, Komaki R, et al. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy+cetuximab for stage III NSCLC. Int J Radiat Oncol Biol Phys. 2017;99:5105.
6. Speirs CK, DeWees TA, Rehan S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol. 2017;12:293–301.
7. Liu W, Patel SH, Shen JJ, et al. Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. Pract Radiat Oncol. 2016;6:e269–e275.
8. Ong CL, Verbelak WF, Culpers JP, Slotman BJ, Lagerwaard FJ, Senan S. Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol. 2010;97:437–442.
9. McGrath SD, Matuszak MM, Yan D, Kestin LL, Martinez AA, Grills IS. Volumetric modulated arc therapy for delivery of hypofractionated stereotactic lung radiotherapy: a dosimetric and treatment efficiency analysis. Radiother Oncol. 2010;95:153–157.
10. Chan OS, Lee MC, Hung AW, Chang AT, Yeung RM, Lee AW. The superiority of hybrid-volumetric arc therapy (VMAT) technique over double arc VMAT and 3D-conformal technique in the treatment of locally advanced non-small cell lung cancer-A planning study. Radiother Oncol. 2011;101:298–302.
11. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.
12. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117:4707–4713.
13. Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80:1350–1357.
14. Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol. 2017;3:e172032–e172032.
15. Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010;77:357–366.
16. Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80:1015–1022.
17. Lomax AJ. Intensity Modulated Proton Therapy: The Potential and the Challenge [Habilitation Thesis]. Zurich: Department of Physics, ETH; 2004.
18. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol. 2008;53:1027–1042.
19. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. Phys Med Biol. 2008;53:1043–1056.
20. Chang JY, Zhang X, Knopf A, et al. Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys. 2017;99:41–50.
21. Chang JY, Li H, Zhu XR, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014;90:809–818.
22. Kraus KM, Heath E, Oelfke U. Dosimetric consequences of tumor motion due to respiration for a scanned proton beam. Phys Med Biol. 2011;56:6553–6581.
23. Lambert J, Suchowierska N, McKenzie DR, Jackson M. Intrafractional motion during proton beam scanning. Phys Med Biol. 2005;50:4853–4862.
24. Grozinger SO, Bert C, Haberer T, Kraft G, Rietzel E. Motion compensation with a scanned ion beam: a technical feasibility study. Radiat Oncol. 2008;3:34.
25. Seco J, Robertson D, Trofimov A, Paganetti H. Breathing interplay effects during proton beam scanning: simulation and statistical analysis. Phys Med Biol. 2009;54:N283–N294.
26. Grozinger SO, Rietzel E, Li Q, Bert C, Haberer T, Kraft G. Simulations to design an online motion compensation system for scanned particle beams. Phys Med Biol. 2006;51:3517–3531.
27. Dowdell S, Grassberger C, Sharp GC, Paganetti H. Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters. Phys Med Biol. 2013;58:4137–4156.
28. Grassberger C, Dowdell S, Lomax A, et al. Motion Interplay as a Function of Patient Parameters and Spot Size in Spot Scanning Proton Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2013;86:380–386.
29. Knopf A-C, Hong TS, Lomax A. Scanned proton radiotherapy for mobile targets-the effectiveness of re-scanning in the context of different treatment planning approaches and for different motion characteristics. Phys Med Biol. 2011;56:7257–7271.
30. Li Y, Kardar L, Li X, et al. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014;41:021721.
31. Kardar L, Li Y, Li X, et al. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014;4:e259–e268.
32. Bortfeld T, Jokivarsi K, Goitein M, Kung J, Jiang SB. Effects of intrafraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol. 2002;47:2203–2220.
33. Phillips MH, Pedroni E, Blattmann H, Boehringer T, Coray A, Scheib S. Effects of respiratory motion on dose uniformity with a charged particle scanning method. Phys Med Biol. 1992;37:223.
34. Inoue T, Widder J, van Dijk LV, et al. Limited impact of setup and range uncertainties, breathing motion and interplay effects in robustly optimized intensity modulated proton therapy for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;96:661–669.
35. Liu W, Liao Z, Schild SE, et al. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Pract Radiat Oncol. 2015;5:e77–e86.
36. Moteabbed M, Yock TI, Depauw N, Madden TM, Koo H, Paganetti H. Impact of spot size and beam-shaping devices on the
37. Liu C, Schild SE, Chang JY, et al. Impact of spot size and spacing on the quality of robustly optimized intensity modulated proton therapy plans for lung cancer. *Int J Radiat Oncol Biol Phys*. 2016;95:190–198.

38. Shen J, Tryggestad E, Younkin JE, et al. Using experimentally determined proton spot scanning timing parameters to accurately model beam delivery time. *Med Phys*. 2017;44:5081–5088.

39. Liu W, Schild S, Chang J, et al. A novel 4D robust optimization mitigates interplay effect in intensity-modulated proton therapy for lung cancer. *Med Phys*. 2015;42:3525–3525.

40. Liu W, Schild SE, Chang JY, et al. Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer. *Int J Radiat Oncol Biol Phys*. 2016;95:523–533.

41. Richter D, Schwarzkopf A, Trautmann J, et al. Upgrade and benchmarking of a 4D treatment planning system for scanned ion beam therapy. *Med Phys*. 2013;40:051722.

42. Bortfeld T, Chan TCY, Trofimov A, Tsitsiklis JN. Robust management of motion uncertainty in intensity-modulated radiation therapy. *Oper Res*. 2008;56:1461–1473.

43. Chan TCY, Bortfeld T, Tsitsiklis JN. A robust approach to IMRT optimization. *Phys Med Biol*. 2006;51:2567–2583.

44. Trofimov A, Rietzel E, Lu HM, et al. Temporo-spatial IMRT optimization: concepts, implementation and initial results. *Phys Med Biol*. 2005;50:2779–2798.

45. Stambaugh C, Nelms BE, Dilling T, et al. Experimentally studied dynamic dose interplay does not meaningfully affect target dose in VMAT SBRT lung treatments. *Med Phys*. 2013;40:091710.

46. Rao M, Wu J, Cao D, et al. Dosimetric impact of breathing motion in lung stereotactic body radiotherapy treatment using image-modulated radiotherapy and volumetric modulated arc therapy. *Int J Radiat Oncol Biol Phys*. 2012;83:e251–e256.

47. Chang JY, Jabbour SK, De Ruyscher D, et al. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. 2016;95:505–516.

48. Liu W, Mohan R, Park P, et al. Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers. *Pract Radiat Oncol*. 2014;4:384–391.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Comparison of the doses to non-target tissues between small-spot IMPT and large-spot IMPT.

Table S2. The field, energy, and estimated delivery duration used in VMAT plans.

Table S3. The field, energy, and delivery duration in the IMPT plans.

Data S1. Comparison of IMPT plan quality with different spot sizes.

Data S2. Comparison with reported large spot size IMPT results.